Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 41.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 112,672 shares of the biotechnology company's stock after selling 80,184 shares during the quarter. Assenagon Asset Management S.A. owned about 0.53% of Enanta Pharmaceuticals worth $622,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. RA Capital Management L.P. acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $5,968,000. Marshall Wace LLP boosted its holdings in shares of Enanta Pharmaceuticals by 9.3% during the fourth quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after acquiring an additional 79,197 shares during the period. Millennium Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 22.7% during the fourth quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock valued at $5,158,000 after acquiring an additional 165,692 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $1,908,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Enanta Pharmaceuticals by 52.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company's stock worth $1,708,000 after purchasing an additional 102,646 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA traded down $0.05 on Friday, hitting $7.18. The company's stock had a trading volume of 183,679 shares, compared to its average volume of 285,193. The company has a market capitalization of $153.51 million, a price-to-earnings ratio of -1.58 and a beta of 0.76. The stock's 50-day moving average is $6.02 and its two-hundred day moving average is $6.10. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The firm had revenue of $14.93 million during the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 149.57% and a negative return on equity of 79.83%. Equities analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ENTA has been the subject of several recent analyst reports. JMP Securities increased their price target on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 3rd. Wall Street Zen cut Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Two equities research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $18.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.